Adam Lavertu

1.0k citations
15 papers · 510 indexed · h-index 11
Topics
Pharmacovigilance and Adverse Drug Reactions (3 papers)Genomics and Rare Diseases (3 papers)Genetic Associations and Epidemiology (3 papers)

In The Last Decade

Adam Lavertu

15 papers receiving 500 citations

Peers

Adam Lavertu
Comparison fields: 5 of 100
  • Molecular Biology 197
  • Genetics 185
  • Pharmacology 157
  • Toxicology 52
  • Pediatrics, Perinatology and Child Health 51
Replace Christina Mitropoulou with:
Christina Mitropoulou Greece
Padmaja Mummaneni United States
Gregory McInnes United States
Yael Garten United States
Marisa Papaluca‐Amati Netherlands
Xuequn Ren China
Jack W. Snyder United States
M. van Vliet Netherlands
Wendy A. Wolf United States
Lisette Binkhorst Netherlands
Adam Lavertu relative to Christina Mitropoulou Greece Christina Mitropoulou's profile →
Citations per field
00.5×6.5×
Christina Mitropoulou · 1×
Citations per year

Countries citing papers authored by Adam Lavertu

Since Specialization
Citations

This map shows the geographic impact of Adam Lavertu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Lavertu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Lavertu more than expected).

Fields of papers citing papers by Adam Lavertu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Lavertu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Lavertu. The network helps show where Adam Lavertu may publish in the future.

Co-authorship network of co-authors of Adam Lavertu

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Lavertu. A scholar is included among the top collaborators of Adam Lavertu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Lavertu. Adam Lavertu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
#WorkIndexed citations
1 3
2 1
3 66
4 8
5 28
6 97
7 4
8 16
9 13
10 68
11 11
12 61
13 44
14 19
15 71

About Adam Lavertu

Adam Lavertu is a scholar working on Toxicology, Family Practice and Pharmacology, having authored 15 papers that have together received 510 indexed citations. Recurring topics across this work include Pharmacovigilance and Adverse Drug Reactions (3 papers), Genomics and Rare Diseases (3 papers) and Genetic Associations and Epidemiology (3 papers). The work is most often cited by research in Pharmacology (157 citations), Toxicology (52 citations) and Genetics (185 citations). Adam Lavertu has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Russ B. Altman, Gregory McInnes, Michelle Whirl‐Carrillo, Teri E. Klein, Manuel A. Rivas, Katrin Sangkuhl, Yosuke Tanigawa, Kathleen M. Giacomini, Bianca Vora and Stefano Rensi. Their work appears in journals such as Nature Communications, Bioinformatics and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026